Toronto, Ontario--(Newsfile Corp. - January 20, 2026) - Therma Bright Inc. (TSXV: THRM) (OTCQB: TBRIF) (FSE: JNX0) ("Therma Bright" or the "Company"), a developer and investment partner specializing in advanced diagnostic and medical device technologies, is pleased to announce it has received a follow-on order for an additional 200 Venowave™ VW5 units from its Texas-based distribution partner, Gen-X Med. This latest transaction marks the expansion of the relationship between the two companies, following th ...

Core Insights - Therma Bright Inc. has expanded its partnership with Gen-X Med to enhance the distribution of its Venowave™ VW5 units, targeting specialized knee surgeons in the U.S. healthcare network [1][2] - The initial sale of 200 units has shown positive patient outcomes, leading to expectations for additional orders as awareness of the product increases [2] - The Venowave™ VW5 is positioned as a significant innovation in the compression therapy market, which is projected to grow from $4.18 billion in 2024 to $6.72 billion by 2033, reflecting a CAGR of 7.30% [2] Company Overview - Therma Bright Inc. specializes in advanced diagnostic and medical device technologies, focusing on solutions that improve patient outcomes and reduce healthcare costs [1][5] - The Venowave™ VW5 is a portable device designed to treat circulatory disorders, enhancing venous blood flow significantly and approved for Medicare reimbursement [3] Industry Context - The global compression therapy market is experiencing robust growth, indicating a rising demand for innovative medical solutions like the Venowave™ VW5 [2] - The partnership with Gen-X Med is a strategic move to penetrate a high-value segment of the U.S. healthcare market, particularly in post-surgical recovery [2][4]